Lupus

Lupus Nephritis Reshapes Pregnancy Risk Beyond confirming that SLE pregnancies remain higher risk, the study highlights two important opportunities: the ability to use large-scale, real-world data to study relatively uncommon outcomes in lupus, and the importance of lupus https://t.co/gI2p1bVDN8

It's like HCQ on steroids (metaphorical not literal, & anabolic not glucocorticoid) TLR7/8 targeting in SLE (IFN-I, GC resistance, organ damage) ph2: massive signal in primary, secondaries all hit, IFN-I down from w2, safety good what a time for lupus ABSTLB23 #ACR26 @RheumNow https://t.co/mhntxC4aT4

https://x.com/drdavidliew/status/2120647650739716478/photo/1

@RheumNow #3. Abstract 0041. Can CAR-T therapy truly “reset” the immune system in lupus? Promising findings show that both patient and donor-derived CAR-T suppress key inflammatory gene signatures in SLE, suggesting a molecular immune reset beyond clinical remission. #ACR26

@RheumNow #4. Continuing the conversation on unmet needs in cSLE. Abstract 2486. The PLUMM trial highlights barriers to clinical trial enrollment in pediatrics. Strict eligibility criteria, patient preference, logistic and feasibility issues limit participation. #ACR2026

@RheumNow My top 5 from #ACR2026. #5. Abstract 2484. Addressing unmet needs in cSLE using #CARRA registry data. cSLE patients have significant burden of unmet therapeutic needs with currently approved therapies. Urgent call to expedite regulatory approvals of cSLE therapies!

@RheumNow Abstract #2483 Pediatric Sjögren’s lacks validated clinical trial endpoints, limiting treatment research. This study developed a prioritized, 8-domain patient-centered endpoint for N-of-1 trials, bridging objective disease activity and lived symptom burden. #ACR26

(2/2) LB22 Both DAZ arms with similar AEs compared to placebo group Signal for symptom response at 4W? Improved pt reported sicca outcomes with 1500mg Q4W dose vs placebo @RheumNow #ACR26

(1/2)#ACRBest Dazodalibep (DAZ) for systemically active SjD Ph3 top line results! LB22 648 pts IV DAZ 1500mg Q4W or 3000mg Q12W vs placebo Signf improved ESSDAI in both DAZ arms @ 48W. ESDAI differences vs placebo -1.8 for 1500mg Q4W, -1.4 for 3000mg Q12W @RheumNow #ACR26

Abstract 2969: surveyed pts w/ lupus about clinical trial awareness - 87% patients reported informed about their dx w/ physicians as main source (94%) - cliniical trial knowledge lower (44%) - 84% expressed interest in trials - travel most common barrier @RheumNow #ACR26

Article

ACR 2026 Day 4 Report

Jack Cush, MD Nov 11, 2026

The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts.

Can We Predict Work Disability in Lupus? When it comes to managing patients with SLE there are many aspects of the disease to consider – disease activity, organs involved, and the potential for long term damage. Given that SLE affects many working-age adults, there is another https://t.co/9Fp4MxKpw9

@RheumNow Determinates of health and outcomes in Rheumatic diseases #2. Lupus nephritis & race: Evidence to support racial/ethnic differences in Rx efficacy is limited. ACR 2024 guidelines do NOT recommend basing treatment decisions on race or ethnicity. #ACR26

Dazodalibep (CD40/CD40L inhibitor) for Sjogren's Improved ESSDAI at both doses compared to PBO Q4 week dosing w/ improvements in dryness Sig. improvement but PBO also did fairly well... how much is an ESSDAI delta of -1.4 to -1.8 clinically meaningful... @RheumNow #ACR26 LB22 https://t.co/AEBtjpJq1F

https://x.com/Dr_Brian_MD/status/2120533479813161024/photo/1

Article

CAR T Gets the Spotlight. Are We Missing the B Cells That Matter?

Melissa Akselrad, MD Nov 11, 2026

CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies we already have?

#Sjogren’s is no longer a #dry #Rx landscape Which to choose in future? #Ianalumab #dazodalibep DIff #MOA #CD40L #CD20 deleted+ altered B cell Signalling +RCTs of each Can’t compare between drugs #efficacy 🤷 #ACR2026 @RheumNow @ACRheum #LB22 #1861 shows #Iana effects https://t.co/73D0ENtcnZ

#FcRn #efigartigimod + #RCT in #IMNM & #DM #LB24 But 😞 #SjD RCT stopped 🛑 for #futility We will have niche Rx for many rare #SARDs I think over next few yrs #ACR26 @ACRheum @RheumNow

ALKIVIA trial: Ph3 RCT of Efgargitimod (EFG) SC for IIM Met primary endpt of achieving TIS vs PBO in IMNM+DM w/ early improvement observed by wk 4 Primary key secondary endpts also met Infection rates similar bet EFG & PBO 1st successful trial in IMNM @RheumNow #ACR26 LB24 https://t.co/Az9cH5Fyhh

Ph2 RCT of Afimetoran (TLR7/8) for SLE: Met primary endpt of SRI-4 for all 3 doses at wk 48 (p<0.001); >30% vs PBO IFN gene suppression as early as wk 24 Afi incr C3/C4, antidsDNA over time Well-tolerated, SAEs comp across all 3 arms, no new safety signals @RheumNow #ACR26 LB23 https://t.co/gBrd7gpOkJ

Primary SRI-4 in active #SLE met W TLR7/8 #AFIMETORAN Wow! RCT is ☑️ Less infections and great high bar outcomes #ACRbest #LB23 @RheumNow @ACRheum https://t.co/cvcWVlBRmC https://t.co/CaRdcR8VWw

NEW #MOA in #SLE TLR7/8 #Afimetoran Drives Interferon T1 TLR7 Changes organ damage TLR8 1 or more background #lupus #Rx mandated #prednisone taper Aim <7.5mg/d #GCs Mean #SLEDAI 8, CLASI 7-8 Mean pred 9.5-10.5 85%HCQ #ACR26 @RheumNow @ACRheum #LB24 https://t.co/EXCnYdc7O3

LB23: Ph2 trial Afimetoran (TLR7/8 inhibitor) in pts w active SLE - all 3 doses higher SRI-4 response v PBO: 64.1%-67.8% vs 34.4% - secondary measures c/w with SRI-4 (BICLA, LLDAS, GC sparing, & others) - infection most common reported AE @RheumNow #ACR26 https://t.co/5WGDCHygcP

https://x.com/AkhilSoodMD/status/2120520168883544262/photo/1

OASIZ-301 Trial- Dazodalibep for SjD Both DAZ arms (3000mg & 1500mg) demonstrated sign. improvements in ESSDAI at wk 48 vs PBO DAZ arms also met key sec endpts - including sign. improved ESSPRI/DASPRI dryness domains w/1500mg Both arms safe & welltolerated @RheumNow #ACR26 LB22 https://t.co/GjnDCWkMG7

Kalunian et al. Phase 2 RCT of Afimetoran, oral TLR 7/8i in SLE. 248 patients. Met SRI-4 in all groups. No dose dependent effect. Less serious adverse events with afimetoran vs placebo. @RheumNow #ACR26 Abstr#LB23 https://t.co/jlTO5OeD2N

https://x.com/RichardPAConway/status/2120518407129096629/photo/1

Noaiseh et al. Phase 3 OASIZ-301 RCT. Dazodalibep in Sjogens. Positive study. Effect by week 4. Secondary outcomes on sicca also met. Similar adverse events to placebo. @RheumNow #ACR26 Abstr#LB22 https://t.co/s4E44IMpS8

https://x.com/RichardPAConway/status/2120516902527062128/photo/1

#Dazodolibep #RCT in #SjD #CD40Li fusion protein no Fc 3 arms - 2 protocols ⬆️signs #ESSDAI>5. Entered >10 Other ⬆️#ESSPRI #Sjogren’s 1 or 2ndary (25%) 93%F -1.8 diff from PBO +results #ACRbest new Rx! #LB22 #ACR26 #ACRbest @RheumNow @ACRheum https://t.co/JJaDp0nCnM